Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

Moderna MRNA shares jumped more than 9% in early trading Friday, reaching a fresh 52-week high as the biotechnology company ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesday after both companies rose in the previous session following reports of a suspected pneumonic plague case in ...

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.

That could leave the stock due for a pullback according to Citi, whose Street-low target of $80 would suggest a nearly 60% ...

The biotech is entering a new era.

Moderna (MRNA) stock rose after confirming Nasdaq-100 inclusion, even as Citi downgrades the stock on valuation concerns.

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund falling 1.89% ...